![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DEPDC7 |
Gene summary for DEPDC7 |
![]() |
Gene information | Species | Human | Gene symbol | DEPDC7 | Gene ID | 91614 |
Gene name | DEP domain containing 7 | |
Gene Alias | TR2 | |
Cytomap | 11p13 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q96QD5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91614 | DEPDC7 | NAFLD1 | Human | Liver | NAFLD | 5.35e-05 | 5.11e-01 | -0.04 |
91614 | DEPDC7 | S43 | Human | Liver | Cirrhotic | 4.78e-05 | -1.58e-01 | -0.0187 |
91614 | DEPDC7 | HCC1_Meng | Human | Liver | HCC | 7.72e-11 | -1.24e-01 | 0.0246 |
91614 | DEPDC7 | cirrhotic1 | Human | Liver | Cirrhotic | 1.17e-02 | -1.48e-01 | 0.0202 |
91614 | DEPDC7 | cirrhotic2 | Human | Liver | Cirrhotic | 2.78e-02 | -1.47e-01 | 0.0201 |
91614 | DEPDC7 | HCC1 | Human | Liver | HCC | 5.22e-03 | 2.42e+00 | 0.5336 |
91614 | DEPDC7 | Pt14.d | Human | Liver | HCC | 4.78e-05 | -1.43e-01 | 0.0143 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DEPDC7 | SNV | Missense_Mutation | novel | c.1508A>G | p.Asp503Gly | p.D503G | Q96QD5 | protein_coding | tolerated(0.06) | benign(0.024) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
DEPDC7 | SNV | Missense_Mutation | novel | c.760N>T | p.Leu254Phe | p.L254F | Q96QD5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DEPDC7 | SNV | Missense_Mutation | c.1069N>A | p.Glu357Lys | p.E357K | Q96QD5 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DEPDC7 | SNV | Missense_Mutation | c.493N>A | p.Asp165Asn | p.D165N | Q96QD5 | protein_coding | tolerated(0.42) | benign(0.006) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
DEPDC7 | SNV | Missense_Mutation | c.1198N>G | p.Leu400Val | p.L400V | Q96QD5 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
DEPDC7 | SNV | Missense_Mutation | novel | c.1433C>A | p.Thr478Asn | p.T478N | Q96QD5 | protein_coding | tolerated(0.41) | benign(0.005) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
DEPDC7 | SNV | Missense_Mutation | novel | c.98T>G | p.Phe33Cys | p.F33C | Q96QD5 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DEPDC7 | SNV | Missense_Mutation | novel | c.1369C>A | p.Gln457Lys | p.Q457K | Q96QD5 | protein_coding | tolerated(0.87) | benign(0) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DEPDC7 | SNV | Missense_Mutation | novel | c.219N>A | p.Asp73Glu | p.D73E | Q96QD5 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DEPDC7 | SNV | Missense_Mutation | c.271N>T | p.Pro91Ser | p.P91S | Q96QD5 | protein_coding | tolerated(1) | benign(0.268) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |